The Alzheimer's Gamble: Biogen's Bold Move and the Future of Drug Development
What if the next breakthrough in Alzheimer's treatment isn’t about slam-dunk results, but about reading between the lines of disappointing data? That’s the question Biogen is forcing us to grapple with as it pushes its experimental Alzheimer’s drug into late-stage trials despite underwhelming mid-stage results. Personally, I think this move is less about confidence and more about desperation—a calculated risk in a field where failure has become the norm. But it’s also a fascinating glimpse into the high-stakes world of pharmaceutical development, where hope often outpaces evidence.
The Tau Tango: A Protein That Won’t Quit
Biogen’s latest drug targets tau, a protein that, alongside amyloid, has become the poster child for Alzheimer’s research. What makes this particularly fascinating is that while amyloid has dominated headlines (thanks to drugs like Adu
